Document is current
Any future updates will be listed below
-
Authors
Ishiguro, Hiroshi https://orcid.org/0000-0002-9859-5932
Masuda, Norikazu
Sato, Nobuaki
Higaki, Kenji
Morimoto, Takashi
Yanagita, Yasuhiro
Mizutani, Makiko
Ohtani, Shoichiro
Kaneko, Koji
Fujisawa, Tomomi
Takahashi, Masato
Kadoya, Takayuki
Matsunami, Nobuki
Yamamoto, Yutaka
Ohno, Shinji
Takano, Toshimi
Morita, Satoshi
Tanaka-Mizuno, Sachiko
Toi, Masakazu
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000003283 at UMIN JapanDocuments that mention this clinical trial
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer
https://doi.org/10.1007/s10549-020-05590-w
-
Funding
Funding for this research was provided by:
Sanofi K.K.
- License Information
-
More Information
Article History
Received: 25 November 2019
Accepted: 6 March 2020
First Online: 13 March 2020
Compliance with ethical standards
:
: KH, TM, YYan, MM, KK, TF, TK, NMat, and STM have no competing interests. HI has no competing financial interests. HI is the member of directors for JBCRG. NMas received honoraria from Chugai, AstraZeneca, Pfizer, Eli-Lilly, Eisai and Takeda, Research funding to institution from Chugai, AstraZeneca, Kyowa-Kirin, MSD, Novartis, Pfizer, Eli-Lilly, Eisai, and Daiichi Sankyo. NMas is the member of directors for JBCRG. NS has financial competing interests with Eisai, Eli-Lilly, and Taiho. SOht received honoraria from Chugai, AstraZeneca, Pfizer, Eli-Lilly, and Eisai. MTa received honoraria from AstraZeneca, Eisai, Eli-Lilly’s and Pfizer, Research funding to institution from Eisai, Kyowa-Hakko Kirin, and Taiho. YYam has non-financial competing interests with Japanese Breast Cancer Society (Board member) and Japan Breast Cancer Research Group (Board member). YYam has financial competing interests with Chugai, AstraZeneca, Pfizer, Novartis, Kyowa-Kirin, Eisai, Eli-Lilly, and Takeda. SOhn has received honoraria from Pfizer, Chugai, AstraZeneca, Taiho, Eli-Lilly, Kyowa-Hakko Kirin, Eisai, Novartis, and Research funding to institution from Taiho and Eisai. TT has financial competing interests with Daiichi Sankyo, Kyowa-Hakko Kirin, Eisai, Pfizer, Eli-Lilly, Ono, Bristol-Myers Squibb, MSD, Merck Serono, Taiho, Novartis, and Chugai. SM received honoraria from AstraZeneca, Bristol-Myers Squibb, Chugai, Eisai, Eli-Lilly, MSD, Pfizer, and Taiho. MTo has financial competing interests with Taiho, Chugai, Takeda, Shimadzu, Eizai, Daiichi Sankyo, Yakult, Kyowa-Hakko Kirin, Konica-Minolta, Pfizer, Eli-Lilly, MSD, Genomic Health, AstraZeneca, Novartis, Bayer, Sanofi, C & C Research Laboratories, Nippon-Kayaku, Bizcom Japan, AFI technologies, A & T, Astellas, DSK, BMS, Ono, Terumo, JBCRG, and KBCRN. MTo is the member of directors for JBCRG, KBCRN, OOTR, Japan Surgical Society, Japan Society Clinical Oncology, Japanese Breast Cancer Society as non-financial competing interests.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the local ethics committee or institutional review board at each institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
